BR0011578A - Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico - Google Patents

Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico

Info

Publication number
BR0011578A
BR0011578A BR0011578-9A BR0011578A BR0011578A BR 0011578 A BR0011578 A BR 0011578A BR 0011578 A BR0011578 A BR 0011578A BR 0011578 A BR0011578 A BR 0011578A
Authority
BR
Brazil
Prior art keywords
citalopram
anxiety disorder
panic attacks
enantiomer
general anxiety
Prior art date
Application number
BR0011578-9A
Other languages
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0011578(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0011578A publication Critical patent/BR0011578A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

"UTILIZAçãO DO S-ENANTIÈMERO DE CITALOPRAM PARA TRATAMENTO DE DISTúRBIO DE ANSIEDADE GERAL OU ATAQUES DE PâNICO". Utilização do (S)-eanatiómero de citalopram ou de um sal do mesmo aceitável na farmacologia, para a preparação de um medicamento útil no tratamento de distúrbio de ansiedade generalizada ou com ataques de pânico.
BR0011578-9A 1999-07-08 2000-07-07 Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico BR0011578A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders

Publications (1)

Publication Number Publication Date
BR0011578A true BR0011578A (pt) 2002-03-26

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011578-9A BR0011578A (pt) 1999-07-08 2000-07-07 Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico

Country Status (38)

Country Link
US (6) US7271194B2 (pt)
EP (4) EP1440690A3 (pt)
JP (1) JP4773011B2 (pt)
KR (1) KR100604176B1 (pt)
CN (1) CN1198610C (pt)
AR (1) AR021155A1 (pt)
AT (1) ATE339955T1 (pt)
AU (6) AU782514B2 (pt)
BG (4) BG110467A (pt)
BR (1) BR0011578A (pt)
CA (4) CA2373757C (pt)
CL (3) CL2008003941A1 (pt)
CO (1) CO5190674A1 (pt)
CY (1) CY1105806T1 (pt)
CZ (1) CZ200270A3 (pt)
DE (1) DE60030861T2 (pt)
DK (1) DK1200081T3 (pt)
EA (1) EA006555B1 (pt)
ES (1) ES2272298T3 (pt)
HK (1) HK1048069B (pt)
HR (1) HRP20010820A2 (pt)
HU (1) HUP0201791A3 (pt)
IL (5) IL146131A0 (pt)
IS (1) IS6137A (pt)
ME (2) MEP2508A (pt)
MX (1) MXPA01011626A (pt)
MY (1) MY143278A (pt)
NO (4) NO329021B1 (pt)
PL (1) PL352030A1 (pt)
PT (1) PT1200081E (pt)
SI (1) SI1200081T1 (pt)
SK (1) SK82002A3 (pt)
TR (4) TR200402277T2 (pt)
TW (1) TWI232101B (pt)
UA (1) UA77645C2 (pt)
WO (1) WO2001003694A1 (pt)
YU (1) YU78701A (pt)
ZA (1) ZA200108856B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
CZ2003396A3 (cs) * 2000-07-21 2003-05-14 H. Lundbeck A/S Inhibitory transportu glycinu
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
HRP20031073A2 (en) 2001-07-31 2004-04-30 Lundbeck & Co As H Crystalline composition containing escitalopram
AU2003237524A1 (en) * 2002-07-08 2004-01-23 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
CN100349885C (zh) * 2002-12-23 2007-11-21 H·隆德贝克有限公司 依他普仑氢溴酸盐及其制备方法
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
WO2005053796A1 (en) * 2003-12-02 2005-06-16 B & B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (pt) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (en) 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
WO1997006792A1 (en) 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
ES2149734T3 (es) * 1997-11-11 2003-02-16 Lundbeck & Co As H Metodo para la preparacion de citalopram.
EP0957099B1 (en) * 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
ATE355054T1 (de) 1998-07-13 2006-03-15 Nps Pharma Inc Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
EP1096927A4 (en) 1998-07-16 2002-09-04 Massachusetts Inst Technology COMPOSITION FOR THE TREATMENT OF STRESS
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
NZ514671A (en) * 1999-04-14 2003-10-31 H Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1276478A2 (en) * 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
TR200402276T2 (tr) 2005-01-24
AU2008264182A1 (en) 2009-01-29
IL146131A (en) 2007-02-11
EP1440689A2 (en) 2004-07-28
DK1200081T3 (da) 2006-12-27
JP4773011B2 (ja) 2011-09-14
DE60030861T2 (de) 2007-05-03
HRP20010820A2 (en) 2003-08-31
CO5190674A1 (es) 2002-08-29
KR100604176B1 (ko) 2006-07-25
EP1440690A3 (en) 2004-08-18
AU5806100A (en) 2001-01-30
HK1048069A1 (en) 2003-03-21
NO20100334L (no) 2002-01-07
WO2001003694A1 (en) 2001-01-18
US20020086899A1 (en) 2002-07-04
BG106279A (bg) 2002-08-30
IL170192A (en) 2010-04-29
MEP2508A (xx) 2010-02-10
NO329021B1 (no) 2010-07-26
BG110468A (en) 2010-01-29
PL352030A1 (en) 2003-07-28
ME00032B (me) 2010-02-10
TR200200014T2 (tr) 2002-05-21
BG110466A (en) 2010-01-29
HUP0201791A3 (en) 2005-02-28
AU2005202685A1 (en) 2005-07-14
CL2008003938A1 (es) 2009-05-22
EP1200081A1 (en) 2002-05-02
AU2005202684A1 (en) 2005-07-14
HUP0201791A2 (en) 2002-10-28
CA2687396A1 (en) 2001-01-18
ATE339955T1 (de) 2006-10-15
NO20100333L (no) 2002-01-07
AR021155A1 (es) 2002-06-12
IS6137A (is) 2001-10-30
CL2008003941A1 (es) 2009-05-22
MXPA01011626A (es) 2002-06-04
AU782514B2 (en) 2005-08-04
US20040029958A1 (en) 2004-02-12
CZ200270A3 (cs) 2002-04-17
NO20020062D0 (no) 2002-01-07
BG110467A (en) 2010-01-29
US7271194B2 (en) 2007-09-18
CA2687392A1 (en) 2001-01-18
YU78701A (sh) 2004-03-12
EP1440690A2 (en) 2004-07-28
EA006555B1 (ru) 2006-02-24
US6960613B2 (en) 2005-11-01
EP1440691A3 (en) 2004-08-25
US20040029956A1 (en) 2004-02-12
CA2373757C (en) 2010-01-05
US20040029957A1 (en) 2004-02-12
AU2005202686B2 (en) 2009-01-15
IL170194A (en) 2010-05-31
CN1198610C (zh) 2005-04-27
US7265151B2 (en) 2007-09-04
EP1200081B1 (en) 2006-09-20
AU2005202684B2 (en) 2009-01-15
ZA200108856B (en) 2002-12-24
AU2008264188A1 (en) 2009-05-07
IL146131A0 (en) 2002-07-25
TR200402277T2 (tr) 2005-01-24
JP2003504332A (ja) 2003-02-04
SK82002A3 (en) 2002-07-02
MY143278A (en) 2011-04-15
HK1048069B (zh) 2005-12-16
EP1440689A3 (en) 2004-08-25
US20070276035A1 (en) 2007-11-29
CY1105806T1 (el) 2011-02-02
KR20020015346A (ko) 2002-02-27
CA2373757A1 (en) 2001-01-18
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CN1360501A (zh) 2002-07-24
CA2687394A1 (en) 2001-01-18
DE60030861D1 (de) 2006-11-02
TR200402275T2 (tr) 2005-03-21
IL170193A (en) 2010-04-29
ES2272298T3 (es) 2007-05-01
AU2005202686A1 (en) 2005-07-14
EA200200137A1 (ru) 2002-06-27
UA77645C2 (en) 2007-01-15
NO20100335L (no) 2002-01-07
AU2005202685B2 (en) 2009-01-15
CL2008003939A1 (es) 2009-06-05
US20050101665A1 (en) 2005-05-12
TWI232101B (en) 2005-05-11
EP1440691A2 (en) 2004-07-28
PT1200081E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
BR0110420A (pt) Agonistas muscarìnicos
BR0213358A (pt) Uso de flibanserina
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
SE0102147D0 (sv) New methods
BR0010802A (pt) Antagonistas de receptor il-8
ATE427107T1 (de) Eine neue verwendung von deferiprone
BR9815098A (pt) Uso de mirtazapina ou de um seu sal farmaceuticamente aceitável, e, processo para o tratamento de apnéias do sono em um aninal.
BR0010084A (pt) Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
BR0112131A (pt) Composições farmacêuticas e métodos para uso
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
TR199500984A2 (tr) Selegilin'in epileptik hastaliklarin tedavisinde kullanimi.
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]